Earnings Releases·Nov 5, 2026, 4:10 PM ET

FocalTherics — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $9.8 million, a 26% year-over-year increase, while net loss narrowed to $4.5 million ($0.10 per share) from $5.9 million in the prior year period, driven by favorable non-cash warrant impacts and foreign currency gains.
Full-year 2026 revenue guidance was narrowed to $50.0–$52.0 million (34–39% growth), reflecting sustained commercial traction and accelerating technology adoption despite a 24% increase in operating expenses to $12.8 million.
U.S. procedure volume accelerated 32% year-over-year, system sales rose 17% to seven units, and the installed base expanded to 192 units, with positive payer coverage published for HIFU in recurrent prostate cancer.
The company holds $56.3 million in cash and cash equivalents as of September 30, 2026, following $50.7 million in cash generated from financing activities over the first nine months of the year.